SugenTech Expects to Exceed Last Year's Sales with COVID-19 Diagnostic Kit Exports

[Asia Economy Reporter Jang Hyowon] SuzenTech announced on the 13th that it has started exporting rapid antibody test kits for COVID-19 to over 40 countries, and within 10 days, the export amount exceeded last year's sales revenue of 3.8 billion KRW.

The export amount recorded until the 10th since the start of exports reached 4.4 billion KRW. This amount includes the 1 billion KRW contract with Indonesia and the 900 million KRW contract in the South American region, which were disclosed on the 10th. After beginning exports on the 31st of last month, SuzenTech achieved results surpassing last year's annual sales within just 10 days.

The order volume that SuzenTech must supply by May this year amounts to 3.5 million units. This exceeds the quantity supplied so far this year, indicating a high possibility of recording the highest performance in the company's history this year. SuzenTech also plans additional facility expansion by the end of April.

Recently, Chinese products supplied to Europe have faced issues regarding quality and accuracy, leading importing countries to conduct clinical trials of diagnostic kits at the government level. As a result of government-level clinical trials conducted by countries in Europe and Asia, SuzenTech's products have proven high accuracy and quality, prompting supply requests from governments worldwide.

A SuzenTech official stated, "Despite supply requests from countries around the world, the demand has surged so rapidly that we cannot meet it, so we are exporting in small quantities divided among over 40 countries," adding, "We are steadily increasing production along with facility expansion, and from May, we expect to produce 1.5 million kits per week, enabling large-scale exports."

This content was produced with the assistance of AI translation services.